1. Type A natriuretic peptides exhibit different bronchoprotective effects in rats
- Author
-
Heinz-Gerd Hoymann, Thomas Flüge, U. Heinrich, Wolf-Georg Forssmann, Thomas O.F. Wagner, Helmut Fabel, and Jens M. Hohlfeld
- Subjects
medicine.medical_specialty ,Muscle Proteins ,Bronchi ,Peptide hormone ,chemistry.chemical_compound ,Atrial natriuretic peptide ,Heart Rate ,Internal medicine ,medicine ,Animals ,Plethysmograph ,Rats, Wistar ,Pharmacology ,Inhalation ,Urodilatin ,Acetylcholine ,Peptide Fragments ,Rats ,Endocrinology ,chemistry ,Breathing ,Female ,Bronchoconstriction ,medicine.symptom ,Atrial Natriuretic Factor ,medicine.drug - Abstract
The protective effect of 11.4, 22.8 or 45.6 pmol/kg/min cardiodilatin/atrial natriuretic peptide (CDD/ANP-(99–126)), urodilatin (CDD/ANP-(95–126)) or vehicle intravenously against acetylcholine-induced bronchoconstriction was compared in spontaneously breathing, halothane-anesthetized Wistar rats. The inhalation of acetylcholine induced significant alterations of the spontaneous breathing parameters evaluated by whole-body plethysmography without significant differences between the treatment groups. Forced parameters detect airflow changes with a greater sensitivity and were measured in hyperventilation-induced temporary apnoea after the challenge. The forced expiratory volume in 0.1 s revealed a significant protective effect of 11.4 pmol/kg/min urodilatin compared to the controls whereas the parameters of the forced expiratory flow-volume curve were significantly preserved by 11.4 and 22.8 pmol/kg/min urodilatin (P < 0.05). Urodilatin showed protective effects against an acetylcholine challenge whereas CDD/ANP-(99–126) was without significant influence.
- Published
- 1994
- Full Text
- View/download PDF